Edition:
United Kingdom

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

11.55USD
17 Aug 2018
Change (% chg)

$0.15 (+1.32%)
Prev Close
$11.40
Open
$11.35
Day's High
$11.60
Day's Low
$11.25
Volume
27,551
Avg. Vol
67,250
52-wk High
$13.35
52-wk Low
$4.70

Latest Key Developments (Source: Significant Developments)

Cytosorbents Files For Mixed Shelf Of Up To $150 Million
Thursday, 26 Jul 2018 

July 26 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING.  Full Article

Cytosorbents Sees Q4 2017 Revenue About $4.6 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER.SEES Q4 2017 REVENUE ABOUT $4.6 MILLION.SEES FY 2017 REVENUE $15 MILLION.- WITH NEW TAX LAW, AND WITH SUBSTANTIAL FEDERAL NET OPERATING LOSSES "WE WILL NOT PAY FEDERAL INCOME TAX FOR A LONG TIME".  Full Article

U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Cytosorbents Corp ::CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION.U.S. FDA GRANTED APPROVAL OF REFRESH 2 INVESTIGATIONAL DEVICE EXEMPTION APPLICATION, WITH CONDITIONS.CONDITIONS RELATE TO REQUESTED CLARIFICATIONS, CHANGES TO PATIENT CONSENT FORM & INSTRUCTIONS FOR USE DOCUMENT.  Full Article

Cytosorbents posts Q3 revenue of $3.8 mln
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cytosorbents Corp :Cytosorbents continues strong trajectory of growth in the third quarter 2017.Total Q3 2017 revenues increased 59% to $3.8 million​.  Full Article

CytoSorbents signs deal with Armaghan Salamat Kish Group to distribute CytoSorb in Iran
Friday, 23 Sep 2016 

CytoSorbents Corp :Has signed an exclusive distribution agreement with Armaghan Salamat Kish Group to distribute CytoSorb in Iran.  Full Article

BRIEF-Cytosorb Adds Bilirubin And Myoglobin Reduction To Eu Approved Indications For Use

* CYTOSORB® ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE